Showing 5081-5090 of 5291 results for "".
- Medical Entrepreneur Symposium Adds Breakout Sessionhttps://practicaldermatology.com/news/20121024-medical_entrepreneur_symposium_adds_breakout_session/2459693/The Medical Entrepreneur Symposium, a unique educational meeting for physicians, their office managers, and executives in healthcare, has added a breakout session for physician entrepreneurs wanting to take great business ideas or medical devices to market. Dr. Arlen Meyers will be the course direct
- ASDS Election Results Announcedhttps://practicaldermatology.com/news/20121023-asds_election_results_announced/2459696/The ASDS has elected new officers and members of its Board of Directors whose terms began at the recent annual meeting in Atlanta. Dr. George Hruza, Clinical Professor of Dermatology and Otolaryngology at St. Louis University, was elected Vice President and will ascend to President-Elect in 2013-14
- Actress Cynthia Nixon Helps Americans to Come Face to Face with Rosaceahttps://practicaldermatology.com/news/20121014-actress_cynthia_nixon_wants_americans_to_come_face_to_face_with_rosacea/2459707/Some of the 16 million Americans affected by rosacea are not seeking therapy, but a new initiative encourages them to come "Face to Face" with the disease. Supported by Galderma in association with the National Rosacea Society
- Celgene to Present Data From Abraxane Melanoma Studyhttps://practicaldermatology.com/news/20121009-celgene_to_present_data_from_abraxane_melanoma_study/2459712/Results from a late-stage clinical trial by Celgene Corp. show its cancer drug Abraxane slows the progression of melanoma. The trial compared Abraxane and dacarbazine in 529 patients with melanoma that had metastasized. The company says that patients treated with Abraxane had greater progression-fre
- Revance Regains Rights to Its Botulinum Toxinshttps://practicaldermatology.com/news/20121009-revance_regains_rights_to_its_botulinum_toxins/2459713/Revance Therapeutics, Inc. announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A.
- Strathspey Crown Hosts Founders Summithttps://practicaldermatology.com/news/20121002-strathspey_crown_hosts_founders_summit/2459717/Strathspey Crown recently hosted its Founders Summit & Retreat at Pelican Hill in Newport Beach, CA. The event gathered approximately 50 of the top physicians from elective healthcare and national leaders from government, healthcare, and f
- Jurlique Offers Holiday Discountshttps://practicaldermatology.com/news/20121002-jurlique_offers_holiday_discounts/2459718/Jurlique released holiday gift sets featuring full-sized product at a 30 to 40 percent savings. The products include: Age-Defying Trio, of Jurlique Purely Age-Defying Serum, Purely Age-Defying Ultra Firm and Lift Cream, and Skin Balancing Face Oi
- Syneron Kicks Off New Campaignhttps://practicaldermatology.com/news/20121002-syneron_kicks_off_new_campaign/2459721/Syneron Medical Ltd. launched a new Break Up. Get Even! campaign for its elure product line. As part of the campaign, five winners will receive a complete elure range of products ($335 value) to “break up” stubborn discoloration and “get even” skin tone. The campaign is run through the company's
- Pharma Penalties Total $10.2B Over Two Yearshttps://practicaldermatology.com/news/20120928-pharma_penalties_total_102b_over_two_years/2459727/Pharmaceutical manufacturers have reached a total of 74 settlements, totaling $10.2 billion in financial penalties with federal and state governments between November 2, 2010 and July 18, 2012. That's the conclusion of an updated report from P
- p53R2 Regulates Proliferation and Chemosensitivity in Melanomahttps://practicaldermatology.com/news/20120918-p53r2_regulates_proliferation_and_chemosensitivity_in_melanoma/2459734/Expression of p53R2 significantly correlates with the depth of invasion and the tumor stage in melanoma, new research shows. (J Dermatol Sci; 68(1):19-24) Furthermore, use of siRNA targeting p53R2 successfully knocked down p53R2 and significantly inhibited the growth of KHm5 and 6 cells. The degree